Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lyrica Generics Launch, But Pfizer Has Been Bracing For The Hit

Executive Summary

The first generic versions of Pfizer's blockbuster pain medicine pregabalin have launched in the US. Pfizer has guided investors the company will return to growth in 2020 after cycling through the loss.

You may also be interested in...



At Pfizer, A Split A Decade In The Making

Pfizer's ambitious plans to spin out its Upjohn branded and generics business will result in a smaller, innovation-focused pharma. The decision comes after nine years of back-and-forth about whether the move would unlock value.

Lyrica Generics Were Likely Delayed By A Pfizer Labeling Supplement

US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.

Lyrica Generics Likely Delayed By A Pfizer Labeling Supplement

US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125581

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel